Alleviant’s Novel Heart Failure Tech Gets FDA Breakthrough Designation
Alleviant Medical received FDA approval to begin a pivotal trial of its no-implant atrial shunt for heart failure patients...
Alleviant Medical received FDA approval to begin a pivotal trial of its no-implant atrial shunt for heart failure patients...
Sana Biotechnology announced positive initial results from a first-in-human study involving a patient with type 1 diabetes. The study,...
MAIA Biotechnology will collaborate with BeiGene to evaluate THIO, MAIA’s telomere-targeting anticancer drug, in combination with BeiGene’s immune checkpoint...
The global retinal gene therapy market is projected to exceed US$110 million in revenue in 2024, driven by the...
BioSkryb Genomics launched ResolveSEQ MRD, a service that enhances the analysis of minimal residual disease (MRD) in hematological malignancies....
Tenvie Therapeutics launched with $200 million in funding to develop small molecule treatments for neurological diseases. The company acquired...
The sales of the top 20 drugs targeting molecular switches have exceeded $30 billion, highlighting the growing importance of...
Quanta Therapeutics announced advancements in its KRAS-directed drug candidates, including FDA IND clearance for QTX3544, a G12V-preferring multi-KRAS inhibitor,...
AerWave Medical completed its first-in-human feasibility study of a novel ultrasound lung denervation therapy for chronic obstructive pulmonary disease...
Bitterroot Bio announced positive Phase 1 results for BRB-002, a first-in-class immune-modulating protein therapy targeting CD47 for atherosclerotic cardiovascular...